Pharmacists' role in buprenorphine management for opioid use disorder: A narrative review

被引:7
|
作者
Cleary, Jacqueline [1 ]
Engle, Amanda [1 ]
Winans, Amanda [2 ]
机构
[1] Albany Coll Pharm & Hlth Sci, Albany, NY USA
[2] Bassett Med Ctr, Cooperstown, NY USA
来源
JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | 2022年 / 5卷 / 02期
关键词
buprenorphine; collaborative care model; collaborative practice model; opioid use disorder; pharmacist; CARE;
D O I
10.1002/jac5.1579
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The continued rise in patients treated for opioid use disorder (OUD) has called for an increase in access to OUD therapies. Pharmacists, who have previously demonstrated their value in various disease states, have begun to address gaps in OUD care by facilitating buprenorphine treatment. The objective was to review current literature and characterize the pharmacists' role in buprenorphine collaborative care models for patients with OUD. PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature, and Google Scholar were queried through May 2021. Studies were included if a pharmacist was part of a care model in which buprenorphine was prescribed for OUD and excluded if there was a pain management indication, a limited pharmacist role, or a survey methodology was used. Eight care models were included in this review. Key characteristics identified were (1) pharmacist role, (2) collaborating prescriber type, (3) clinic setting, (4) pharmacist practice type, and (5) outcomes. All models were located within a variety of outpatient settings. No collaborative practice model involved autonomous buprenorphine prescriptive authority by pharmacists. The majority utilized a psychiatrist as a collaborating prescriber, alongside a psychiatry-trained pharmacist. Less than half utilized pharmacists to make dosing recommendations. Outcomes evaluating treatment retention and relapse rates were most reported. Most outcomes identified across each model were either improved or unchanged by pharmacist involvement. Pharmacists are valued members of buprenorphine care teams across a variety of settings, collaborate with various clinicians, and have a positive impact on patient outcomes such as treatment retention and relapse. Few published collaborative care models exist, suggesting pharmacists may be underutilized in caring for this growing patient population. The role of the pharmacist in buprenorphine management is not currently well-defined; however, pharmacists are well prepared to take a more active role to help address the opioid crisis.
引用
收藏
页码:228 / 238
页数:11
相关论文
共 50 条
  • [11] Availability and Opportunities for Expansion of Buprenorphine for the Treatment of Opioid Use Disorder
    McKendrick, Greer
    Stull, Samuel W.
    Sharma, Anjalee
    Dunn, Kelly E.
    SEMINARS IN NEUROLOGY, 2024, 44 (04) : 419 - 429
  • [12] Evaluating outcomes of a clinical pharmacist medication management program in a multidisciplinary practice for outpatient buprenorphine treatment of opioid use disorder
    Mattle, Anna G.
    Aladeen, Traci
    Blondell, Richard D.
    Capote, Horacio
    Rainka, Michelle
    JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2021, 4 (04): : 424 - 434
  • [13] The experience of buprenorphine implant in patients with opioid use disorder: a series of narrative interviews
    Scurti, Pietro
    Nunzi, Marco
    Leonardi, Claudio
    Pierlorenzi, Claudio
    Marenzi, Roberta
    Lamartora, Vincenzo
    FRONTIERS IN PSYCHIATRY, 2023, 14
  • [14] Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder
    Schiff, Davida M.
    Nielsen, Timothy C.
    Hoeppner, Bettina B.
    Terplan, Mishka
    Hadland, Scott E.
    Bernson, Dana
    Greenfield, Shelly F.
    Bernstein, Judith
    Bharel, Monica
    Reddy, Julia
    Taveras, Elsie M.
    Kelly, John F.
    Wilens, Timothy E.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 225 (04) : 424.e1 - 424.e12
  • [15] Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy
    Johnson, Shakevia
    Martin, Peter R.
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2018, 44 (03) : 310 - 316
  • [16] The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review
    Jordan, Colleen G.
    Kennalley, Amy L.
    Roberts, Alivia L.
    Nemes, Kaitlyn M.
    Dolma, Tenzing
    Piper, Brian J.
    PHARMACY, 2022, 10 (03)
  • [17] Using buprenorphine to treat patients with opioid use disorder
    Radi, Joshua K.
    Fogarty, Kieran J.
    Lagerwey, Mary D.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2019, 32 (10): : 30 - 35
  • [18] Acute Pain Management for Patients Maintained on Sublingual Buprenorphine as Medication for Opioid Use Disorder
    Haines, Alexander J.
    Wood, Katlyn C.
    Costello, Jennifer L.
    Tawil, Tara
    JOURNAL OF ADDICTION MEDICINE, 2023, 17 (06) : 662 - 669
  • [19] Optimizing opioid use disorder treatment with naltrexone or buprenorphine
    Rudolph, Kara E.
    Diaz, Ivan
    Luo, Sean X.
    Rotrosen, John
    Nunes, Edward, V
    DRUG AND ALCOHOL DEPENDENCE, 2021, 228
  • [20] Pharmacists and the opioid crisis: A narrative review of pharmacists' practice roles
    Bratberg, Jeffrey P.
    Smothers, Zachary P. W.
    Collins, Kathryn
    Erstad, Brian
    Veve, Jennifer Ruiz
    Muzyk, Andrew J.
    JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2020, 3 (02): : 478 - 484